Hematologic (Blood)

NRG – S2209 at https://www.clinicaltrials.gov/study/NCT05561387

A Phase III randomized trial for newly diagnosed multiple myeloma (NDMM) patients considered frail or in a subset of “intermediate fit,” comparing upfront three-drug induction regimens followed by double- or single-agent maintenance

Cancer Type: Multiple myeloma, newly diagnosed

Principal Investigator: Dr. Ryan Devine

75276617AML3001 / cAMeLot-2 (JNJ) - Acute Myeloid Leukemia

NCT06852222

A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy

Principle Investigator: Ryan Devine, DO

Please contact Clinical Trials Office for more details: 561-263-5791